Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.49 USD -11.07% Intraday chart for Indaptus Therapeutics, Inc. +7.33% +41.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Premarket Gainers MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Gainers MT
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial CI
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20 CI
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20 CI
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20 CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20 CI
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023 CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
INDAPTUS THERAPEUTICS SHARES UP 11.4% AFTER POSITIVE PRE-CLINIC… RE
Indaptus Therapeutics, Inc. Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at American Association for Cancer Research Conference 2023 CI
Indaptus Therapeutics, Inc. Announces Executive Changes CI
HC Wainwright Adjusts Price Target on Indaptus Therapeutics to $12 From $15, Maintains Buy Rating MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Indaptus Therapeutics, Inc. Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors CI
Indaptus Therapeutics, Inc. Doses First Subject in Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors CI
Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors CI
HC Wainwright Reiterates Indaptus Therapeutics at Buy With $15 Price Target MT
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors CI
Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Lincoln Park Capital, LLC CI
Chart Indaptus Therapeutics, Inc.
More charts
Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.49 USD
Average target price
10 USD
Spread / Average Target
+301.61%
Consensus
  1. Stock
  2. Equities
  3. Stock Indaptus Therapeutics, Inc. - Nasdaq
  4. News Indaptus Therapeutics, Inc.
  5. Indaptus Therapeutics : Gets Notice of Allowance for Patent Related to Treatment Platform for Hepatitis B, HIV Infections